Drug Database · Clinicians

Diazepam

Brands (6) Valium, Vexepam, Anxiep…Show all

Benzodiazepine US FDA class
Anxiolytics (benzodiazepine derivatives) PH FDA category

S2 · Dangerous drug — PDEA S2 license required; see prescription rules belowRx · Prescription drug9 PH productsPNF-listedVAT-exempt

1971 Convention Schedule IV; Philippine Schedule 4; PDEA S-2 license required. Oral FDA-registered Philippine Schedule 4 preparations: ordinary prescription in triplicate (BR 1 s.2014 Sec. 4(4)(a)); other forms: DOH Special Prescription Form (yellow) (Sec. 31(2)). No refill; up to a 30-day supply, 60 days for epilepsy and dystonia (Sec. 31(6)(d)-(e)). Until June 30, 2027, S-2 licensed practitioners may use an ordinary prescription in triplicate instead of the special form (one dangerous drug per prescription, "NO REFILL", up to 30 days; 60 days for Philippine Schedule 4 drugs in epilepsy and dystonia) (BR 10 s.2025, extended by BR 5 s.2026). Source: DDB, Updated Lists of Scheduled Controlled Substances (as of 20 July 2026); Republic Act No. 9165, Comprehensive Dangerous Drugs Act of 2002; DDB Board Regulation No. 3, s. 2020 (CBD drug products; defines Philippine Schedules 1-4); DDB Board Regulation No. 1, s. 2014 (amending BR 3 s. 2003: licensing, prescriptions, exemptions); DDB Board Regulation No. 10, s. 2025 (temporary authorization of ordinary prescriptions for dangerous drugs); DDB Board Regulation No. 5, s. 2026 (ordinary prescriptions for dangerous drugs extended to June 30, 2027).

Dispensing: Prescription (Rx) · Dangerous drug (S2) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 260e2041-2bb3-482f-850e-b5d47a7bdbe6, version date October 6, 2026 (Valium · Waylis Therapeutics LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • VALIUM is indicated for the: Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE VALIUM is indicated for the: Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal Adjunctive treatment of skeletal muscle spasm due to: reflex spasm to local pathology spasticity caused by upper motor neuron disorders athetosis stiff-person syndrome Adjunctive treatment of seizure disorders Limitations of Use The effectiveness of VALIUM for long-term use (greater than 4 months) has not been evaluated. VALIUM is not recommended as maintenance monotherapy for the treatment of seizure disorders.

VALIUM is a benzodiazepine indicated for the: (1) Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal Adjunctive treatment of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, or stiff-person syndrome Adjunctive treatment of seizure disorders Limitations of Use The effectiveness of VALIUM for long-term use (greater than 4 months) has not been evaluated (1) VALIUM is not recommended as maintenance monotherapy for the treatment of seizure disorders (1)

Contraindications

4 CONTRAINDICATIONS VALIUM is contraindicated in patients with: Known hypersensitivity to diazepam or any of the excipients of VALIUM Acute narrow-angle glaucoma [see Warnings and Precautions (5.9)] Known hypersensitivity to diazepam or any excipients of VALIUM (4) Acute narrow-angle glaucoma (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Recommended oral dosage in adults less than 65 years of age: (2.1)
  • Indication Recommended Oral Dosage Treatment of anxiety disorders 2 mg to 10 mg, two to four times daily Short-term treatment of anxiety symptoms 2 mg to 10 mg, two to four times daily Treatment of acute alcohol withdrawal See full prescribing information for complete indication (1) 10 mg, three to four times during the first 24 hours; after 24 hours reduce to 5 mg, three to four times daily, as needed Recommended dosage is intended for most patients. Based on severity of symptoms some patients may require higher dosages. In such cases, increase dosage gradually. Adjunctive treatment of skeletal muscle spasm 2 mg to 10 mg, three to four times daily Adjunctive treatment of seizure disorders 2 mg to 10 mg, two to four times daily See full prescribing information for recommended oral dosage in pediatric patients 6 months of age and older, geriatric or debilitated patients, and patients with hepatic impairment (2.2)
2.1 Recommended Dosage in Adults Less Than 65 Years of Age

2.1 Recommended Dosage in Adults Less Than 65 Years of Age Table 1 provides the recommended oral dosage of VALIUM by indication for adults less than 65 years of age. Table 1: Recommended Dosage in Adults Less than 65 Years of Age Indication Recommended Oral Dosage Short-term treatment of anxiety symptoms 2 mg to 10 mg, two to four times daily Treatment of acute alcohol withdrawal [see Indications and Usage (1) for the complete indication] 10 mg, three to four times during the first 24 hours; after 24 hours reduce dosage to 5 mg, three to four times daily, as needed.

The recommended dosage is intended for most patients. However, based on severity of symptoms, some patients may require higher dosages. In such cases, increase the dosage gradually, as needed and tolerated, to reduce the risk of adverse reactions. Adjunctive treatment of skeletal muscle spasm 2 mg to 10 mg, three to four times daily Adjunctive treatment of seizure disorders 2 mg to 10 mg, two to four times daily

2.2 Recommended Dosage in Specific Populations Pediatric Patients 6 Months of Age and Older

2.2 Recommended Dosage in Specific Populations Pediatric Patients 6 Months of Age and Older The recommended starting dosage in pediatric patients 6 months of age and older is 1 mg to 2.5 mg orally, three or four times daily. Increase the dosage gradually as needed and tolerated [see Use in Specific Populations (8.4)]. Geriatric or Debilitated Patients The recommended starting dosage in geriatric patients 65 years of age and older or debilitated patients is 2 mg to 2.5 mg orally, once or twice daily.

Increase the dosage gradually as needed and tolerated [see Use in Specific Populations (8.5, 8.8)]. Patients with Hepatic Impairment In patients with mild or moderate hepatic impairment, reduce the recommended dosage by half compared to those with normal hepatic function [see Dosage and Administration (2.1)]. VALIUM is not recommended in patients with severe hepatic impairment [see Use in Specific Populations (8.6)].

2.3 Discontinuation or Dosage Reduction

2.3 Discontinuation or Dosage Reduction of VALIUM To reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALIUM or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly [see Warnings and Precautions (5.3), Drug Abuse and Dependence (9.3)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Patients with Renal Impairment In chronic renal failure, elimination of diazepam, as indicated by clearance of unbound drug, was similar to that in healthy volunteers; thus steady-state concentrations of unbound diazepam at any given daily dose on the average should not be different between patients with renal impairment and healthy individuals.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Patients with hepatic impairment are more sensitive to adverse reactions associated with VALIUM, including increased susceptibility to sedation and delirium [Clinical Pharmacology (12.3)]. The recommended dosage of VALIUM in patients with mild or moderate hepatic impairment is half the recommended dosage as those with normal hepatic function [see Dosage and Administration (2.2)]. Valium is not recommended in patients with severe hepatic impairment.

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use VALIUM is indicated for use in pediatric patients for the: Treatment of anxiety disorders Short-term treatment of anxiety symptoms Treatment of tremor, acute agitation, hallucinosis, and impending delirium tremens or delirium tremens in acute alcohol withdrawal Adjunctive treatment of skeletal muscle spasm due to: reflex spasm to local pathology spasticity caused by upper motor neuron disorders athetosis stiff-person syndrome Adjunctive treatment of seizure disorders Paradoxical reactions are more likely to occur in pediatric patients than in adult patients [see Warnings and Precautions (5.7)]. VALIUM is not recommended for use in pediatric patients less than 6 months of age.

Prolonged central nervous system depression has been observed in neonates treated with diazepam.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Extensive accumulation of diazepam and its major metabolite, des-methyldiazepam, has been noted following chronic administration of diazepam in healthy geriatric male subjects [see Clinical Pharmacology (12.3)]. Metabolites of VALIUM are substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function than in patients with normal renal function.

Because geriatric patients are more likely to have decreased renal function, care should be taken in dosage selection. A lower starting dosage is recommended, and the dosage should be increased gradually as needed and tolerated, to reduce the risk of adverse reactions [see Dosage and Administration (2.2)]. Paradoxical reactions are more likely to occur in geriatric patients compared to younger adult patients [see Warning and Precautions (5.7)

Dosage forms

Philippines

  • Tablet: 5 mg, 10 mg
  • ) solution for injection: 5 mg/mL (10 mg/2 mL
  • Solution for injection: 5 mg/mL

Registered products in the Philippines

9 products registered with the Food and Drug Administration (FDA) Philippines list Diazepam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products9
Philippine FDA-registered products for Diazepam
Package insert
AnxiepDiazepam
5 mg TabletAlu/PVC Blister Pack x 10's (Box of 20's)
RxVAT-exempt
Akciju Sabiedrība "Grindeks" (Site I)Latvia
Ambica International Corporation
DRP-14145
Jun 30, 2028
AnxiolDiazepam
5 mg/mL Solution for Injection (IM/IV)Amber glass ampoule x 2 mL Box of 10's
RxVAT-exempt
Tai Yu Chemical & Pharmaceutical Co., LtdR.O.C
Endure Medical Inc.
DR-XY29833
Aug 9, 2027
LorcamDiazepam
5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL Box of 50's
RxVAT-exempt
T.P. Drug Laboratories (1969) Co., Ltd.Thailand
LORDLA PHARMA SALES
DR-XY22760-B
Nov 20, 2028
ValiumDiazepam
10 mg TabletAlu/PVC Blister Pack x 25's (Box of 100's)
RxVAT-exempt
Recipharm Leganes S.L.U.Spain
DKSH Market Expansion Services Philippines, Inc.Trader: Athnas Pharma UK Limited
DR-XY37748
Apr 7, 2030
ValiumDiazepam
5 mg TabletAlu/PVC Blister Pack x 25's (Box of 100's)
RxVAT-exempt
Recipharm Leganés S.L.U.Spain
DKSH Market Expansion Services Philippines, Inc.Trader: Atnahs Pharma UK Limited
DR-XY37749
Jan 30, 2030
ValiumDiazepam
5 mg/mL (10 mg/2 mL) Solution for Injection (IM/IV)Clear and Colorless Glass Ampoule x 2 mL (Box of 10's)
RxVAT-exempt
CENEXI SASFrance
DKSH MARKET EXPANSION SERVICES PHILIPPINES, INC.Trader: ATNAHS PHARMA UK LIMITED
DR-6298
Apr 14, 2028
ValzepamDiazepam
5 mg/mL Solution for Injection (IM/IV)2 mL Amber Colored Glass Ampoule (Box of 50's)
RxVAT-exempt
L.B.S. Laboratory Ltd. Part.Thailand
Importer: Phil Pharmawealth, Inc.
DR-XY27221
Dec 21, 2026
VexepamDiazepam
10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Mercury Laboratories Ltd.India
Phil. Pharmawealth, Inc.
DR-XY41081
Jul 26, 2027
VexepamDiazepam
5 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Mercury Laboratories Ltd.India
Phil. Pharmawealth, Inc.
DR-XY41080
Jul 26, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS VALIUM tablets are round, flat-faced and scored with a V-shaped perforation and beveled edges: 2 mg: white, engraved with 2 and VALIUM® on the outside edge and vertically scored on reverse side 5 mg: yellow, engraved with 5 and VALIUM® on the outside edge and vertically scored on reverse side 10 mg: blue, engraved with 10 and VALIUM ® on the outside edge and vertically scored on reverse side Tablets: 2 mg, 5 mg, 10 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Central Nervous System (CNS) Depression: Caution patients against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Avoid alcohol and use other medications that produce CNS depression with caution (5.4, 7.2)
  • Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior (5.5)
  • Worsening of Preexisting Depression: Monitor for worsening of preexisting depression (5.6)
  • Paradoxical Reactions: Gradually discontinue VALIUM if paradoxical reactions occur (5.7)
  • Respiratory Depression and Apnea: Use with caution in patients with impaired respiratory function related to concurrent disease process. Consider discontinuing VALIUM if signs and symptoms of respiratory depression or apnea occur in any patient (5.8)
  • Glaucoma: Can increase intraocular pressure in patients with glaucoma. May be used in patients with open-angle glaucoma only if receiving appropriate therapy (4, 5.9) Neonatal Sedation and Withdrawal Syndrome: VALIUM use during pregnancy can result in neonatal sedation and/or neonatal withdrawal syndrome. (5.10, 8.1)
5.1 Risks from Concomitant Use with Opioids

5.1 Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including VALIUM, and opioids may result in profound sedation, respiratory depression, coma, and death [see Drug Interactions (7.1)]. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe VALIUM concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation.

In patients already receiving an opioid analgesic, prescribe a lower initial dose of VALIUM than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking VALIUM, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

Advise both patients and caregivers about the risks of respiratory depression and sedation when VALIUM is used with opioids.

5.2 Abuse, Misuse, and Addiction

5.2 Abuse, Misuse, and Addiction The use of benzodiazepines, including VALIUM, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)].

Before prescribing VALIUM and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of VALIUM, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of VALIUM along with monitoring for signs and symptoms of abuse, misuse, and addiction.

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

5.3 Dependence and Withdrawal Reactions

5.3 Dependence and Withdrawal Reactions To reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALIUM or reduce the dosage (a patient-specific plan should be used to taper the dose) [see Dosage and Administration (2.3)]. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.

Acute Withdrawal Reactions The continued use of benzodiazepines, including VALIUM, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of VALIUM after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence (9.3)].

Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see Drug Abuse and Dependence (9.3)].

5.4 Central Nervous System Depression

5.4 Central Nervous System Depression Benzodiazepines, including VALIUM, may produce central nervous system (CNS) depression. Caution patients receiving VALIUM against engaging in hazardous occupations or activities requiring complete mental alertness (e.g., operating machinery or driving a motor vehicle). Alcohol should be avoided and medications that produce CNS depression should be used with caution during treatment with VALIUM [Drug Interactions (7.2)].

5.5 Suicidal Behavior and Ideation

5.5 Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including VALIUM, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.

There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.

Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication.

The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs. Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis Indication Placebo Patients with Events Per 1000 Patients Drug Patients with Events Per 1000 Patients Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients Risk Differences: Additional Drug Patients with Events Per 1000 Patients Epilepsy 1.0 3.4 3.5 2.4 Psychiatric 5.7 8.5 1.5 2.9 Other 1.0 1.8 1.9 0.9 Total 2.4 4.3 1.8 1.9 The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.

Anyone considering prescribing VALIUM or any other AED must balance the risk of suicidal thoughts or behaviors with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.

Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.

5.6 Worsening of Preexisting Depression

5.6 Worsening of Preexisting Depression Benzodiazepines, including VALIUM, may worsen preexisting depression [see Warnings and Precautions (5.5)]. Monitor patients for worsening of preexisting depression. Appropriate precautions (e.g., limiting the total prescription size) should be considered.

5.7 Paradoxical Reactions

5.7 Paradoxical Reactions Paradoxical reactions, such as aggression, agitation, anger, irritability, psychoses, hallucinations, anxiety, nightmares, and increased muscle spasticity have been reported during benzodiazepine use [see Adverse Reactions (6)]. These reactions are more likely to occur in pediatric and geriatric patients.

Gradually discontinue VALIUM if paradoxical reactions occur [see Dosage and Administration (2.3)].

5.8 Respiratory Depression and Apnea

5.8 Respiratory Depression and Apnea Use of benzodiazepines, including VALIUM, either alone or in combination with other CNS depressants, may lead to potentially fatal respiratory depression [see Warnings and Precautions (5.4)]. In patients with impaired respiratory function treated with benzodiazepines, respiratory depression and apnea have been reported.

Use VALIUM with caution in patients with impaired respiratory function related to a concurrent disease process [see Use in Specific Populations (8.7)]. If signs and symptoms of respiratory depression or apnea occur in any patient, consider discontinuing VALIUM.

5.9 Glaucoma

5.9 Glaucoma Benzodiazepines, including VALIUM, can increase intraocular pressure in patients with glaucoma. VALIUM may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALIUM is contraindicated in patients with acute narrow-angle glaucoma.

5.10 Neonatal Sedation and Withdrawal Syndrome

5.10 Neonatal Sedation and Withdrawal Syndrome Maternal use of VALIUM late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to diazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to diazepam during pregnancy for signs of withdrawal; manage these neonates accordingly [see Use in Specific Populations (8.1)].

Drug interactions

Drug interactions (US label) US FDA label
  • 7 Drug Interactions CYP3A4 and CYP2C19 Inhibitors: Based on tolerability, consider reducing dosage of VALIUM. Avoid food or drink containing grapefruit (7.3)
  • CYP3A4 and CYP2C19 Inducers: Based on clinical response, consider increasing dosage of VALIUM (7.3)
7.1 Effect of Concomitant Use of Benzodiazepines and Opioids

7.1 Effect of Concomitant Use of Benzodiazepines and Opioids Limit dosage and duration of concomitant use of VALIUM and opioids and monitor patients closely for respiratory depression and sedation. The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration.

Benzodiazepines interact at gamma-aminobutyric acid (GABAA) sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists [see Warnings and Precautions (5.1)].

7.2 CNS Depressants and Alcohol

7.2 CNS Depressants and Alcohol Avoid consumption of alcohol and use caution during concomitant use of other medications that produce CNS depression with VALIUM. VALIUM produces additive CNS depressant effects, which can include potentially fatal respiratory depression, when used concomitantly with other medications that produce CNS depression, or with consumption of alcohol [see Warnings and Precautions (5.4, 5.8)].

7.3 Effects of Other Drugs

7.3 Effects of Other Drugs on VALIUM Table 3 describes drug interactions where concomitant use of another drug affects VALIUM. Table 3: Concomitant Use of Other Drugs That Affect VALIUM CYP3A4 or CYP2C19 Inhibitors See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 and CYP2C19 inhibitors and inducers.

Prevention or Management Based on tolerability, consider reducing the dosage of VALIUM during concomitant use with CYP3A4 or CYP2C19 inhibitors. Avoid food or drink containing grapefruit juice during treatment with VALIUM. Mechanism and Clinical Effect(s) Concomitant use of CYP3A4 or CYP2C19 inhibitors with VALIUM increases the exposure of VALIUM and may lead to increased and prolonged sedation.

CYP3A4 or CYP2C19 Inducers Prevention or Management Based on clinical response, consider increasing the dosage of VALIUM during concomitant use with CYP3A4 or CYP2C19 inducers. Mechanism and Clinical Effect(s) Concomitant use of VALIUM with CYP3A4 or CYP2C19 inducers may decrease the exposure of VALIUM and lead to decreased efficacy.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Elimination Metabolism Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A.

Drug Interaction Studies The metabolism of diazepam and its main metabolite, desmethyl-diazepam depends on the cytochrome P450 isozymes CYP3A4 and CYP2C19.

Inhibitors of CYP3A4 and CYP2C19 decrease metabolic rate and may lead to higher concentrations of diazepam and the desmethyl metabolite.

Inducers of CYP3A4 and CYP2C19 may lead to lower concentrations of diazepam and the desmethly metabolite [see Drug Interactions (7.3) ] .

Effect of Other Drugs on the Pharmacokinetics of Diazepam Enzyme Inhibitors Grapefruit juice contains strong inhibitors of CYP3A4.

Antimycotic azole derivatives inhibit CYP3A4 and CYP2C19 pathways and lead to increased exposure to diazepam and prolonged elimination half-life of diazepam [see Drug Interactions (7.3) ] .

The histamine H 2 -receptor antagonist cimetidine, an inhibitor of multiple CYP isozymes, including CYP3A4 and CYP2C19, reduces the clearance of diazepam and of desmethyl-diazepam and results in higher exposure and a prolonged elimination half-life of diazepam and its main metabolite [see Drug Interactions (7.3) ] .

The calcium channel blocker diltiazem, a substrate for the same CYP isozymes as diazepam and an inhibitor of CYP3A4, increased AUC and prolonged half-life of diazepam [see Drug Interactions (7.3) ] .

Adverse reactions

Adverse reactions (US label) US FDA label

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1)] Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2] Dependence and Withdrawal Reactions [see Warnings and Precautions (5.3)] Central Nervous System Depression [see Warnings and Precautions (5.4)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.5)] Worsening of Preexisting Depression [see Warnings and Precautions (5.6)] Paradoxical Reactions [see Warnings and Precautions (5.7)] Respiratory Depression and Apnea [see Warnings and Precautions (5.8)] Glaucoma [see Warnings and Precautions (5.9)] Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.10)] The following adverse reactions associated with the use of VALIUM were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following adverse reactions have also been reported: Blood and lymphatic disorders: neutropenia Eye disorders: blurred vision, diplopia Gastrointestinal disorders: changes in salivation, including dry mouth and hypersalivation, gastrointestinal disturbances, constipation, nausea Hepatobiliary disorders: jaundice Injury, poisoning and procedural complications: falls and fractures.

The risk is increased in those taking concomitant CNS depressants (including alcohol) and in geriatric patients. Investigations: elevated transaminases and alkaline phosphatase Nervous system disorders: vertigo, dizziness, dysarthria, tremor, headache Changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after VALIUM therapy.

Psychiatric disorders: disorientation, confusional state, decreased alertness, inappropriate behavior, emotional and mood disturbances, depression, acute hyperexcited states, hyperactivity, restlessness, stimulation, anxiety, nervousness, aggressiveness, agitation, anger, hostility, irritability, psychoses, delusions, hallucinations, insomnia, sleep disturbances, abnormal dreams, nightmares Anterograde amnesia has been reported, with the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior.

Skin and subcutaneous tissue disorders: skin reactions Urogenital disorders: incontinence, changes in libido, urinary retention Vascular disorders: hypotension Most common adverse reactions are drowsiness, fatigue, muscle weakness, and ataxia (6) To report SUSPECTED ADVERSE REACTIONS, contact Waylis at 1-303-557-7642or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Exposure Registries There are pregnancy exposure registries that monitor pregnancy outcomes in women exposed to psychiatric medications and antiepileptic drugs (AEDs), including VALIUM, during pregnancy. Healthcare providers are encouraged to advise patients to register by contacting the appropriate registry below: The National Pregnancy Registry for Psychiatric Medications by calling 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.

The North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see Warnings and Precautions (5.10) and Clinical Considerations].

Available data from published observational studies of pregnant women exposed to benzodiazepines do not support a clear association with benzodiazepines and major birth defects (see Data). There are risks to the mother and fetus associated with untreated epilepsy during pregnancy (see Clinical Considerations). In animal studies, administration of diazepam during the organogenesis period of pregnancy resulted in increased incidences of fetal malformations at doses greater than those used clinically.

Data for diazepam and other benzodiazepines suggest the possibility of increased neuronal cell death and long-term effects on neurobehavioral and immunological function based on findings in animals following prenatal or early postnatal exposure at clinically relevant doses (see Data). The background risk of major birth defects and miscarriage for the indicated populations are unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryofetal Risk Epilepsy, with or without exposure to antiepileptic drugs, has been associated with several adverse outcomes during pregnancy, including preeclampsia, preterm labor, antepartum and postpartum hemorrhage, placental abruption, poor fetal growth, prematurity, fetal death, and maternal mortality.

The risk of maternal or fetal injury may be greatest for patients with untreated or poorly controlled convulsive seizures. Females with epilepsy should not discontinue diazepam abruptly due to the risk of status epilepticus or severe seizures, which may be life-threatening [see Warnings and Precautions (5.3)]. Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates.

Monitor neonates exposed to VALIUM during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to VALIUM during pregnancy for signs of withdrawal. Manage these neonates accordingly [see Warnings and Precautions (5.10)]. Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.

Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, recent case-control and cohort studies of benzodiazepine use during pregnancy were adjusted for confounding exposures to alcohol, tobacco and other medications; these studies did not support an association with benzodiazepines and major birth defects.

Animal Data Diazepam has been shown to cause malformations when administered orally to pregnant mice and hamsters during the period of organogenesis at doses of 100 mg/kg/day or greater, approximately 12 and 20 times the maximum recommended human dose (MRHD) based on mg/m 2 body surface area, respectively. Cleft palate and encephalopathy were the most common and consistently reported malformations produced at maternally toxic doses of diazepam.

Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term changes in cellular immune responses, brain neurochemistry, and behavior. In published animal studies, administration of benzodiazepines or other drugs that enhance GABAergic inhibition to neonatal rats has been reported to result in widespread apoptotic neurodegeneration in the developing brain at clinically relevant plasma concentrations.

The window of vulnerability to these changes in rats (postnatal days 0-14) includes a period of brain development that takes place during the third trimester of pregnancy in humans.

Mechanism of action

12.1 Mechanism of Action The mechanism of action of diazepam for the listed indications [see Indications and Usage (1)] is thought to involve potentiation of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter, resulting from binding at the benzodiazepine site of the GABA A receptor.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The effects of diazepam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications. Diazepam-induced psychomotor impairment in women on contraceptives may be higher during the 7-day menstrual pause when off the hormone preparation than when taking the contraceptive. There is some limited evidence that benzodiazepines can increase the incidence of break-through bleeding in women with hormonal contraceptives.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The initial distribution phase has a half-life of approximately 1 hour, although it may range up to >3 hours.

Diazepam has an initial rapid and extensive distribution phase being followed by a prolonged terminal elimination phase (half-life up to 48 hours).

The terminal elimination half-life of the active metabolite N-desmethyldiazepam is up to 100 hours.

Excretion Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates.

Diazepam accumulates upon multiple dosing and there is some evidence that the terminal elimination half-life is slightly prolonged.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption After oral administration >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 to 1.5 hours with a range of 0.25 to 2.5 hours. Following daily dosing, diazepam levels reach a steady state within approximately 5 days and desmethyl diazepam levels reach a steady state within approximately 10 days.

Average steady-state levels of diazepam after once daily administration are approximately twice as high as the peak levels of the drug after the first dose. Effect of Food Absorption is delayed and decreased when administered with a moderate fat meal. In the presence of food, mean lag times are approximately 45 minutes as compared with 15 minutes when fasting.

There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting. This results in an average decrease in C max of 20% in addition to a 27% decrease in AUC (range 15% to 50%) when administered with food. Distribution Diazepam and its metabolites are highly bound to plasma proteins (diazepam 98%).

The volume of distribution at steady-state is 0.8 to 1.0 L/kg. Diazepam and its metabolites cross the blood-brain and placental barriers. The decline in the plasma concentration-time profile after oral administration is biphasic. The initial distribution phase has a half-life of approximately 1 hour, although it may range up to >3 hours.

Both protein binding and volume of distribution of desmethyl-diazepam are similar to those of diazepam. Elimination Metabolism Oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A. Diazepam is mainly metabolized to pharmacologically active metabolites such as desmethyl-diazepam, a pathway accounting for 50 to 60% of total diazepam clearance; 3-hydroxylation (27% of total diazepam clearance) is slow, leading to only low plasma levels of the oxidation products temazepam and oxazepam.

Temazepam and oxazepam are further conjugated to glucuronides. After multiple doses of diazepam, plasma concentration ratios of desmethyl-diazepam to diazepam were 1.1 ± 0.2, temazepam to diazepam 0.11 ± 0.05, and oxazepam to diazepam 0.09 ± 0.03. Diazepam has an initial rapid and extensive distribution phase being followed by a prolonged terminal elimination phase (half-life up to 48 hours).

The terminal elimination half-life of the active metabolite N-desmethyldiazepam is up to 100 hours. Excretion Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates. The clearance of diazepam is 20 to 30 mL/min in young adults. Diazepam accumulates upon multiple dosing and there is some evidence that the terminal elimination half-life is slightly prolonged.

Specific Populations Geriatric Patients Age decreases the capacity of the liver for N-demethylation and 3-hydroxylation of diazepam. Elimination half-life increases by approximately 1 hour for each year of age beginning with a half-life of 20 hours at 20 years of age. This appears to be due to an increase in volume of distribution with age and a decrease in clearance.

Consequently, geriatric patients may have lower peak concentrations, and on multiple dosing higher trough concentrations. It will also take longer to reach steady-state [see Dosage and Administration (2.2), Use in Specific Populations (8.5)]. Conflicting information has been published on changes of plasma protein binding in geriatric patients.

Pediatric Patients In pediatric patients 3 to 8 years of age the mean half-life of diazepam has been reported to be 18 hours [see Dosage and Administration (2.2)]. Patients with Renal Impairment In chronic renal failure, elimination of diazepam, as indicated by clearance of unbound drug, was similar to that in healthy volunteers; thus steady-state concentrations of unbound diazepam at any given daily dose on the average should not be different between patients with renal impairment and healthy individuals.

Patients with Hepatic Impairment In mild and moderate cirrhosis, average half-life is increased. The average increase has been variously reported from 2-fold to 5-fold, with individual half-lives over 500 hours reported. There is also an increase in volume of distribution, and average clearance decreases by almost half. Mean half-life is also prolonged with hepatic fibrosis to 90 hours (range 66 to 104 hours), with chronic active hepatitis to 60 hours (range 26 to76 hours), and with acute viral hepatitis to 74 hours (range 49 to129).

In chronic active hepatitis, clearance is decreased by almost half [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Drug Interaction Studies The metabolism of diazepam and its main metabolite, desmethyl-diazepam depends on the cytochrome P450 isozymes CYP3A4 and CYP2C19. Modulators of these enzymes may lead to changes in diazepam disposition and effects.

Inhibitors of CYP3A4 and CYP2C19 decrease metabolic rate and may lead to higher concentrations of diazepam and the desmethyl metabolite. Inducers of CYP3A4 and CYP2C19 may lead to lower concentrations of diazepam and the desmethly metabolite [see Drug Interactions (7.3)]. Effect of Other Drugs on the Pharmacokinetics of Diazepam Enzyme Inhibitors Grapefruit juice contains strong inhibitors of CYP3A4.

Diazepam exposure was increased and time to reach maximum concentration was delayed when diazepam was given with grapefruit juice instead of water [see Drug Interactions (7.3)]. Antimycotic azole derivatives inhibit CYP3A4 and CYP2C19 pathways and lead to increased exposure to diazepam and prolonged elimination half-life of diazepam [see Drug Interactions (7.3)].

The serotonin reuptake inhibitor fluvoxamine is also an inhibitor of both of diazepam's degradation pathways and increased not only exposure to diazepam and prolonged its elimination half-life but also increased exposure and time to reach steady-state of the desmethyl metabolite. Fluoxetine showed a more moderate effect on diazepam AUC [see Drug Interactions (7.3)].

Combined hormonal contraceptives appear to reduce the clearance and prolong elimination half-life of diazepam. Proton pump inhibitors such as omeprazole, esomeprazole, lansoprazole, pantoprazole may increase the diazepam AUC. The histamine H 2 -receptor antagonist cimetidine, an inhibitor of multiple CYP isozymes, including CYP3A4 and CYP2C19, reduces the clearance of diazepam and of desmethyl-diazepam and results in higher exposure and a prolonged elimination half-life of diazepam and its main metabolite [see Drug Interactions (7.3)].

No such pharmacokinetic interaction was seen with the H 2 -receptor antagonists ranitidine and famotidine. Disulfiram inhibits the metabolism of diazepam and likely the further metabolism of diazepam's active metabolites. Antituberculosis therapy may change the disposition of diazepam. In the presence of isoniazid, diazepam mean exposure (AUC) and half-life were increased.

The calcium channel blocker diltiazem, a substrate for the same CYP isozymes as diazepam and an inhibitor of CYP3A4, increased AUC and prolonged half-life of diazepam [see Drug Interactions (7.3)]. The primary metabolite of idelalisib is a strong CYP3A4 inhibitor and increases the serum concentrations of diazepam [see Drug Interactions (7.3)].

The psychostimulants modafinil and armodafinil induce CYP3A4 and inhibit CYP2C19; they may prolong the elimination of diazepam [see Drug Interactions (7.3)]. Enzyme Inducers Rifampicin and carbamazepine, potent inducers of CYP3A4, may lead to a reduction in exposure of diazepam [see Drug Interactions (7.3)]. Antacids Antacids may lower the diazepam peak but have no effect on the extent of absorption of diazepam.

Diazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The time to reach peak concentrations are 20-25 min longer for diazepam in presence of antacids. Effect of Diazepam on the Pharmacokinetics of Other Drugs Diazepam has not been found to induce or inhibit metabolizing enzymes.

Diazepam is a substrate for CYP2C19 and CYP3A4; therefore, VALIUM may interfere with the metabolism and increase the exposure of drugs which are sensitive substrates for CYP2C19 and CYP3A4.13

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Diazepam 5 mg/mL, 2 mL Ampule₱40.68–₱136.34Reference ₱74.34per ampuleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Diazepam
PNF listingOral: 5 mg tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Dangerous drug: DOH Official Prescription Form (yellow Rx), S2 license, no refill (PNF code A1)
PNF listingInj.: 5 mg/mL, 2 mL ampul (IM, IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Dangerous drug: DOH Official Prescription Form (yellow Rx), S2 license, no refill (PNF code A1)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Valium · Waylis Therapeutics LLC [US FDA-approved label, version 12, October 6, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e2041-2bb3-482f-850e-b5d47a7bdbe6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .